Sensitivity, specificity, NPV and PPV of FIT for CRC and adenoma within TWW, NG12 and DG30 pathways
| CRC | TWW (N=612) (95% CI) | NG12 (N=519) (95% CI) | DG30 (N=79) (95% CI) |
| Sensitivity | 86.84% (71.91% to 95.59%) | 84.85% (68.1% to 94.89%) | 100% (47.82% to 100%) |
| Specificity | 82.23% (78.85% to 85.27%) | 81.28% (77.52% to 84.65%) | 91.89% (83.18% to 96.97%) |
| NPV | 98.95% (97.66% to 99.53%) | 98.75% (97.23% to 99.44%) | 100% |
| PPV | 24.44% (20.69% to 28.63%) | 23.63% (19.57% to 28.01%) | 45.45% (27.9% to 64.22%) |
| Adenoma | TWW (N=612) (95% CI) | NG12 (N=519) (95% CI) | DG30 (N=19) (95% CI) |
| Sensitivity | 30.69% (21.9% to 40.66%) | 30.77% (21.51% to 41.32%) | 25.00% (3.19% to 65.09%) |
| Specificity | 79.65% (75.89% to 83.06%) | 78.8% (74.82% to 82.79%) | 86.48% (75.27% to 92.44%) |
| NPV | 85.32% (83.53% to 86.96%) | 87.17% (82.13% to 86.01%) | 91.43% (87.61% to 94.15%) |
| PPV | 22.96% (17.51% to 29.51%) | 23.93% (18.01% to 86.01%) | 16.66% (5.02% to 43.1%) |
CRC, colorectal cancer; FIT, faecal immunochemical test; NPV, negative predictive value; PPV, positive predictive value; TWW, 2-week wait.